Question 32

Zyprexa Relprevv is subject to a REMS program.

Zyprexa Relprevv is a medication that requires a Risk Evaluation and Mitigation Strategy (REMS) due to its potential risks and the need for careful monitoring in patients. This program is designed to ensure that the benefits of the medication outweigh the risks associated with its use.

A) Seroquel XR

Seroquel XR is an atypical antipsychotic but is not subject to a REMS program. While it does have potential side effects, it has not been identified by the FDA as needing the additional safety measures that a REMS entails.

B) Abilify Maintena

Abilify Maintena, an injectable formulation of aripiprazole, is also not subject to a REMS program. Although it has specific prescribing guidelines, it does not require the same level of risk management as medications under a REMS.

C) Risperdal Consta

Risperdal Consta is another antipsychotic medication that does not fall under the REMS program. Despite its side effects and monitoring needs, it has not been classified by the FDA as requiring a REMS for its distribution.

D) Zyprexa Relprevv

Zyprexa Relprevv is subject to a REMS program due to the risk of post-injection delirium/sedation syndrome, which can occur after administration. This program mandates specific requirements for healthcare providers and pharmacies to ensure patient safety and proper use.

Conclusion

Zyprexa Relprevv is the only medication listed that is subject to a REMS program, highlighting the importance of safety measures in managing its associated risks. The other options, while they may have safety concerns, do not require the stringent monitoring and risk management that Zyprexa Relprevv necessitates. This distinction underscores the critical nature of the REMS program in protecting patients who use certain high-risk medications.